Results 121 to 130 of about 26,729 (245)
Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion
Journal of the European Academy of Dermatology and Venereology, EarlyView.Systematic review of 108 studies with a total of 182 patients with interstitial granulomatous dermatitis (IGD). IGD was frequently associated with systemic conditions or drug exposure. Management includes careful medication review and prompt withdrawal of potential triggers. Corticosteroids (systemic and topical) were commonly effective, while biologic
Francesco Bellinato +4 more
wiley +1 more source
Sulfasalazine: Dissolution and Distribution in Pharmaceutically Relevant Mediums
, 2016 The sulfasalazine melting temperature and molar enthalpy have been determined by the DSC method. The shake flask method has been used to measure the drug solubility in buffer solutions (pH 2.0 and 7.4), hexane, and octanol and to determine the ...
Marina V. Ol’khovich (1995505) +3 more
core +1 more source
Sustained Remission of Pediatric Bowel‐Associated Dermatosis‐Arthritis Syndrome With Risankizumab
Pediatric Dermatology, EarlyView.ABSTRACT Bowel‐associated dermatosis‐arthritis syndrome (BADAS) is a rare neutrophilic dermatosis characterized by recurrent fever, arthralgias, and skin eruptions, most commonly occurring in patients with inflammatory bowel disease. We report the case of a 17‐year‐old female with Crohn's disease who developed BADAS and achieved complete and durable ...
Kylie E. Peake +4 more
wiley +1 more source
The Journal of Physiology, EarlyView.Abstract figure legend Suboptimal maternal nutrition alters placental and developing blood–brain barrier (BBB) protective function and is associated with increased fetal brain vulnerability. In the placenta, nutritional adversity may reduce the exchange surface area and promote meta‐inflammation, compromising barrier efficiency in a model‐ and context ...
Kristin L. Connor +4 more
wiley +1 more source
Retractions in Rheumatology: Trends, Causes, and Implications for Research Integrity
Arthritis Care &Research, Volume 78, Issue 10, Page 1372-1379, October 2026.Objective We aimed to describe the trends and main reasons for study retraction in rheumatology literature. Methods We reviewed the Retraction Watch database to identify retracted articles in rheumatology. We recorded the main study characteristics, authors’ countries, reasons for retraction, time from publication to retraction, and trends over time ...
Anna Maria Vettori, Michele Iudici
wiley +1 more source
The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites.
, 1996 The anti-inflammatory mechanism of sulfasalazine is not well understood. It has recently been shown that sulfasalazine inhibits 5-aminoimidazole-4-carboxamidoribonucleotide (AICAR) transformylase, an enzyme involved in de novo purine biosynthesis.
Naime, D +8 more
core +1 more source
Arthritis Care &Research, Volume 78, Issue 10, Page 1510-1521, October 2026.People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley +1 more source
Arthritis &Rheumatology, Volume 78, Issue 10, Page 2160-2170, October 2026.Objective Immune checkpoint inhibitors (ICIs) for cancer can lead to immune‐related adverse events, including ICI‐associated inflammatory arthritis (ICI‐IA). There are no validated International Classification of Diseases (ICD) code–based case definitions for ICI‐IA.
Manar Elsayed +11 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1101-1110, October 2026.NAT2 encodes arylamine N‐acetyltransferase 2, a key enzyme in the phase II metabolism of arylamines and arylhydrazines. NAT2 is highly polymorphic, resulting in variable distributions of rapid and poor metabolizers across global populations. Here, we detail the process undertaken by the Clinical Pharmacogenetics Implementation Consortium (CPIC) NAT2 ...
Bailey M. Tibben +10 more
wiley +1 more source
Tocilizumab for severe and refractory mucous membrane pemphigoid
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1682-1691, October 2026.Elevated IL‐6 levels identified in mucous membrane pemphigoid support IL‐6 blockade, with tocilizumab demonstrating clinical benefit in nine patients with severe and refractory mucous membrane pemphigoid. Abstract Background Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially ...
Billal Tedbirt +20 more
wiley +1 more source